| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2022 | 103.25% | Morgan Stanley | $8 → $5 | Maintains | Equal-Weight |
| 08/25/2022 | 509.76% | Alliance Global Partners | → $15 | Initiates Coverage On | → Buy |
| 08/23/2022 | 143.9% | Truist Securities | $10 → $6 | Maintains | Hold |
| 06/22/2022 | 509.76% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 01/28/2022 | 265.85% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/24/2021 | 265.85% | Morgan Stanley | → $9 | Initiates Coverage On | → Equal-Weight |
| 10/19/2021 | 387.8% | Truist Securities | → $12 | Initiates Coverage On | → Buy |
Celularity Questions & Answers
The latest price target for Celularity (NASDAQ: CELU) was reported by Morgan Stanley on September 12, 2022. The analyst firm set a price target for $5.00 expecting CELU to rise to within 12 months (a possible 103.25% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Celularity (NASDAQ: CELU) was provided by Morgan Stanley, and Celularity maintained their equal-weight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celularity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celularity was filed on September 12, 2022 so you should expect the next rating to be made available sometime around September 12, 2023.
While ratings are subjective and will change, the latest Celularity (CELU) rating was a maintained with a price target of $8.00 to $5.00. The current price Celularity (CELU) is trading at is $2.46, which is out of the analyst's predicted range.